other material
confidence high
sentiment positive
materiality 0.85
Altimmune reports positive Phase 2 RECLAIM trial of pemvidutide in alcohol use disorder
Altimmune, Inc.
- Primary endpoint met: reduction in heavy drinking days/week vs placebo (LS mean diff -1.45, p=0.0014).
- 64.4% of pemvidutide patients achieved 2-level reduction in WHO Risk Drinking Level vs 34.8% placebo (p=0.0049).
- Zero heavy drinking days in 42.2% of pemvidutide patients vs 17.4% placebo (p=0.0066).
- Placebo-adjusted body weight reduction of 9.1% at 24 weeks (p<0.0001); no plateauing observed.
- Company plans to request End-of-Phase 2 meeting with FDA based on these results.